An Indian health-tech startup, Healthify, announced plans to deepen collaborations with weight-loss drug manufacturers after forging an initial partnership with the India unit of Novo Nordisk. The company aims to build a global patient-support network for users of GLP-1 receptor agonist weight-loss therapies.
Healthify launched a patient-support program offering tailored coaching and guidance for individuals prescribed Novo Nordisk’s GLP-1 drugs, which have become increasingly popular among patients with obesity or overweight. According to the startup, services related to weight-loss drug support already contribute substantially to its revenues, and it expects the GLP-1 program to account for over one-third of its paid subscriptions within the next year.
With over 45 million global users and a six-digit paid subscriber base, Healthify views India as a critical market. The company plans to extend its support services internationally, betting on increasing demand and rising competition from firms such as Eli Lilly, as well as anticipated entry of generic alternatives post-2026.
The move reflects a broader trend: as weight-loss drugs become more widely prescribed, demand grows not only for the drugs themselves but also for support systems that help patients manage treatment — including dosing schedules, lifestyle advice, diet and exercise coaching, and long-term follow-up. Healthify positions itself as a middle-ground provider bridging pharmaceutical therapy and patient guidance.
This development may signal a shift in how obesity treatment is delivered, especially in emerging markets where healthcare infrastructure and long-term patient monitoring may be less comprehensive. By offering structured support along with medication, companies like Healthify could help improve adherence, maximize therapeutic efficacy, and reduce dropout rates.
Yet challenges remain. Despite the growing demand, regulatory hurdles, reimbursement policies, and varying healthcare access across countries could limit the scalability of such programs. Additionally, long-term data on safety, effectiveness, and adherence for GLP-1–based weight-loss therapies remain limited. Observers warn that medication alone cannot replace comprehensive lifestyle interventions.
Still, Healthify’s expansion illustrates how the weight-loss landscape is evolving beyond standalone drugs. As more patients turn to GLP-1 therapies, support services may play an increasingly central role — potentially reshaping obesity treatment from episodic prescriptions to integrated care models.
Related topic：
